Rituximab
- TRADE NAMES: MabThera (Roche); Rituxan (Genentech)
- INDICATIONS: Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rhematoid arthritis (in combination with methotrexate), granulomatosis with polyangiitis and mycroscopic polyangiitis (in combination with glucocorticoids)
- CLASS: Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), CD20-directed cytolytic monoclonal antibody, Disease-modifying antirheumatic drug (DMARD), Immunosuppressant, Monoclonal antibody
- HALF-LIFE: 60 hours (after first infusion)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Benazepril, Captopril, Certolizumab, Cisplatin, Clevidipine, Enalapril, Fosinopril, Irbesartan, Lisinopril, Olmesartan, Quinapril, Ramipril
PREGNANCY CATEGORY: C
FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of rituximab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/19/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric